488,932 LeMaitre Vascular, Inc. $LMAT Shares Sold by Conestoga Capital Advisors LLC

Conestoga Capital Advisors LLC decreased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 35.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 878,581 shares of the medical instruments supplier’s stock after selling 488,932 shares during the quarter. LeMaitre Vascular accounts for about 2.2% of Conestoga Capital Advisors LLC’s investment portfolio, making the stock its 16th largest holding. Conestoga Capital Advisors LLC’s holdings in LeMaitre Vascular were worth $72,562,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. purchased a new position in LeMaitre Vascular during the 2nd quarter worth approximately $314,075,000. Boston Trust Walden Corp acquired a new stake in shares of LeMaitre Vascular during the 3rd quarter valued at about $28,546,000. Ranger Investment Management L.P. bought a new stake in LeMaitre Vascular in the second quarter worth approximately $21,045,000. Rice Hall James & Associates LLC acquired a new position in LeMaitre Vascular during the second quarter worth $18,223,000. Finally, Bank of New York Mellon Corp acquired a new stake in LeMaitre Vascular in the 2nd quarter worth approximately $16,549,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Performance

Shares of NASDAQ LMAT opened at $87.92 on Thursday. The business has a fifty day simple moving average of $81.38 and a 200 day simple moving average of $94.16. The company has a current ratio of 16.31, a quick ratio of 13.96 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $2.01 billion, a price-to-earnings ratio of 30.85, a PEG ratio of 2.32 and a beta of 0.51. LeMaitre Vascular, Inc. has a one year low of $78.22 and a one year high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.04). The company had revenue of $67.97 million during the quarter, compared to the consensus estimate of $67.39 million. LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The business’s revenue was up 11.3% on a year-over-year basis. During the same quarter last year, the company earned $0.75 earnings per share. Sell-side analysts expect that LeMaitre Vascular, Inc. will post 2.89 EPS for the current year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Thursday, November 19th will be given a dividend of $0.25 per share. The ex-dividend date is Thursday, November 19th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.1%. LeMaitre Vascular’s payout ratio is presently 35.09%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Weiss Ratings lowered shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, October 23rd. Wells Fargo & Company decreased their price target on shares of LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating for the company in a report on Wednesday, August 5th. Citigroup reaffirmed a “market outperform” rating on shares of LeMaitre Vascular in a research report on Tuesday, July 21st. Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Finally, Wall Street Zen lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Three research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, LeMaitre Vascular presently has an average rating of “Hold” and a consensus price target of $110.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a medical device company focused on the treatment of peripheral vascular disease. The company develops, manufactures and markets products used primarily by vascular surgeons and other specialists in open vascular surgery procedures.

Its product portfolio includes biological and synthetic vascular grafts, carotid shunts, embolectomy and thrombectomy catheters, valvulotomes, vessel closure devices, vascular patches and surgical instruments. These products are designed to support procedures involving the arteries and veins, including the repair, reconstruction and treatment of diseased or obstructed blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular sells its products through a combination of direct sales personnel and distributors.